Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-01-25
2005-01-25
Davis, Zinna Northington (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S317000, C514S345000, C546S001000, C546S192000, C546S301000
Reexamination Certificate
active
06846830
ABSTRACT:
Use of compounds of the formula (I) where A, E, R1, R2, p and q have the meanings given in the specification are GluR6 antagonists useful for the treatment of disorders of the central nervous system.
REFERENCES:
Clark et al, European Journal of Pharmacology, vol. 27, pp. 34-39, 1974.*
Waters et al, Journal of Medicinal Chemistry, vol. 29, pp. 1512-1561, 1986.
Baker Stephen Richard
Bleakman David
Lamas-Peteira Carlos
Anderson Arvie J.
Davis Zinna Northington
Eli Lilly and Company
Winter Mark A.
LandOfFree
Naphtalene derivatives and their pharmaceutical use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Naphtalene derivatives and their pharmaceutical use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Naphtalene derivatives and their pharmaceutical use will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3430830